Image

A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

Recruiting
5 - 35 years of age
Both
Phase 1

Powered by AI

Overview

This is a non-randomized, open label, single-site, single-dose, phase 1 study in up to 5 participants (between 5 and 35 years of age, inclusive) with Transfusion-dependent α-thalassemia. The study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (HSCT) using GMCN-508A Drug Product [autologous CD34+ hematopoietic stem cells transduced with GMCN-508A lentiviral vector encoding the human α-globin gene].

Description

Subject participation for this study will be 5 years.

Eligibility

Inclusion Criteria:

  1. The subject himself/herself or one legal guardian/agent of the subject is required to fully understand the study and voluntarily sign a written informed consent.
  2. Ages 5 to 35, no gender limitation.
  3. The clinical diagnosis of Transfusion-dependent α-Thalassemia.Transfusion dependence was defined as ≥6 Units of transfusions of pRBCs for the prior 24 weeks without >56 days of non-transfusion.
  4. Karnofsky Level of Performance (KPS) score or Lansky Level of Performance (LPS) score ≥70.
  5. Subjects were determined to undergo autologous hematopoietic stem cell transplantation and conditioning procedure by the principle investigator.
  6. Subjects were willing to comply with the protocol.
  7. Fertile Subjects are willing to take effective contraceptive measures during the study.

Exclusion Criteria:

  1. Diagnosed with mild α-thalassemia, Hb Bart's edema, ATRx α-thalassemia, hemoglobin S/β-thalassemia, myelodysplastic subtype anemia, or with HbE homozygous β gene mutation, or with any type of β-thalassemia Thalassemia.
  2. Uncorreted Bleeding disorders with frequent bleeding (eg, menorrhagia, epistaxis, coagulation disorders).
  3. Bacterial, fungal, parasitic or viral infection as determined by the investigator to be clinically significant.
  4. Presence of severe iron overload.
  5. Any prior or current malignancy, myeloproliferative disorders or immunodeficiency disorders.
  6. Any major medical disease, laboratory test abnormality or mental illness that would render the participant ineligible for the study.
  7. Immediate family member with a known Familial Cancer Syndrome.
  8. Prior receipt of gene therapy, allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation.
  9. Participation in another clinical study with an investigational drug 3 months prior to Screening.
  10. Pregnancy, plan to be pregnant during study or breastfeeding in a postpartum female.
  11. Known hypersensitivity to any ingredients or excipients of the test drug.
  12. Eligible for allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation with a known and available donor.
  13. Any other condition that would render the participant ineligible for the study, as determined by the investigator.

Study details

Transfusion-dependent α-Thalassemia

NCT05757245

First Affiliated Hospital of Guangxi Medical University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.